Viktoriya Paroder

Dr. Viktoriya Paroder

Memorial Sloan Kettering Cancer Center, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2003 in Endocrine Reviews
Verified
Journal Article
Closed access
ODOrsolya Dohan
Orsolya Dohan
AVAntonio De La Vieja
Antonio De La Vieja
VPViktoriya Paroder
Viktoriya Paroder
CRClaudia Riedel
Claudia Riedel
MAMona Artani
Mona Artani
NCNancy Carrasco
Nancy Carrasco
The Na+/I− symporter (NIS) is an integral plasma membrane glycoprotein that mediates active I− transport into the thyroid follicular cells, the first step in thyroid hormone biosynthesis. NIS-mediated thyroidal I− transport from the bloodstream to the colloid is a vectorial process made possible by the selective targeting of NIS to the basolateral membrane. NIS also mediates active I− transport in other tissues, including salivary glands, gastric mucosa, and lactating mammary gland, in which it translocates I− into the milk for thyroid hormone biosynthesis by the nursing newborn. NIS provides the basis for the effective diagnostic and therapeutic management of thyroid cancer and its metastases with radioiodide. NIS research has proceeded at an astounding pace after the 1996 isolation of the rat NIS cDNA, comprising the elucidation of NIS secondary structure and topology, biogenesis and posttranslational modifications, transcriptional and posttranscriptional regulation, electrophysiological analysis, isolation of the human NIS cDNA, and determination of the human NIS genomic organization. Clinically related topics include the analysis of congenital I− transport defect-causing NIS mutations and the role of NIS in thyroid cancer. NIS has been transduced into various kinds of cancer cells to render them susceptible to destruction with radioiodide. Most dramatically, the discovery of endogenous NIS expression in more than 80% of human breast cancer samples has raised the possibility that radioiodide may be a valuable novel tool in breast cancer diagnosis and treatment.

10 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
OZOliver Zivanovic
Oliver Zivanovic
DCDennis S. Chi
Dennis S. Chi
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
JKJason A. Konner
Jason A. Konner
RORoisin O'cearbhaill
Roisin O'cearbhaill
PURPOSE: The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.MATERIALS AND METHODS: Patients were intraoperatively randomly assigned to carboplatin HIPEC (800 mg/m2for 90 minutes) or no HIPEC, followed by five or six cycles of postoperative IV carboplatin-based chemotherapy, respectively. Based on a binomial single-stage pick-the-winner design, an arm was considered winner if ≥ 17 of 49 patients were without disease progression at 24 months post-surgery. Secondary objectives included postoperative toxicity and HIPEC pharmacokinetics.RESULTS: Of 98 patients, 49 (50%) received HIPEC. Complete gross resection was achieved in 82% of the HIPEC patients and 94% of the standard-arm patients. Bowel resection was performed in 37% of patients in the HIPEC arm compared with 65% in the standard ( P = .008). There was no perioperative mortality and no difference in use of ostomies, length of stay, or postoperative toxicity. At 24 months, eight patients (16.3%; 1-sided 90% CI, 9.7 to 100) were without progression or death in the HIPEC arm and 12 (24.5%; 1-sided 90% CI, 16.5 to 100) in the standard arm. With a medium follow-up of 39.5 months, 82 patients progressed and 37 died. The median progression-free survival in the HIPEC and standard arms were 12.3 and 15.7 months, respectively (hazard ratio, 1.54; 95% CI, 1 to 2.37; P = .05). There was no significant difference in median overall survival (52.5 v 59.7 months, respectively; hazard ratio, 1.39; 95% CI, 0.73 to 2.67; P = .31). These analyses were exploratory.CONCLUSION: HIPEC with carboplatin was well tolerated but did not result in superior clinical outcomes. This study does not support the use of HIPEC with carboplatin during secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer.

9 May 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
VPViktoriya Paroder
Viktoriya Paroder
SSShelly R. Spencer
Shelly R. Spencer
MPMonika Paroder
Monika Paroder
Diego ArangoDiego Arango
Diego Arango
Simó Schwartz Jr.Simó Schwartz Jr.
Simó Schwartz Jr.
NCNancy Carrasco
Nancy Carrasco
We report an extensive characterization of the Na + /monocarboxylate transporter (SMCT), a plasma membrane protein that mediates active transport of monocarboxylates such as propionate and nicotinate, and we show that SMCT may play a role in colorectal cancer diagnosis. SMCT, the product of the SLC5A8 gene, is 70% similar to the Na + /I − symporter, the protein that mediates active I − uptake in the basolateral surface of thyrocytes and other cells. SMCT was reported in the apical surface of thyrocytes and formerly proposed also to transport I − and was called the apical I − transporter. However, it is now clear that SMCT does not transport I − . Here we demonstrate a high-affinity Na + -dependent monocarboxylate transport system in thyroid cells, which is likely to be SMCT. We show that, whereas thyroidal Na + /I − symporter expression is thyroid-stimulating hormone (TSH)-dependent and basolateral, SMCT expression is TSH-independent and apical not only in the thyroid but also in kidney and colon epithelial cells and in polarized Madin–Darby canine kidney cells. We determine the kinetic parameters of SMCT activity and show its inhibition by ibuprofen ( K i = 73 ± 9 μM) in Xenopus laevis oocytes. SMCT was proposed to be a tumor suppressor in colon cancer [Li, H., et al. (2003) Proc. Natl. Acad. Sci. USA 100, 8412–8417]. Significantly, we show that higher expression of SMCT in colon samples from 113 colorectal cancer patients correlates with longer disease-free survival, suggesting that SMCT expression may be a favorable indicator of colorectal cancer prognosis.

27 June 2019 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
JPJennifer S. Golia Pernicka
Jennifer S. Golia Pernicka
JGJohan Gagniere
Johan Gagniere
JCJayasree Chakraborty
Jayasree Chakraborty
RYRikiya Yamashita
Rikiya Yamashita
LNLorenzo Nardo
Lorenzo Nardo
MGMarc J. Gollub
Marc J. Gollub

29 July 2021 in European Radiology
Verified
Journal Article
Closed access
PDF file
VJVetri Sudar Jayaprakasam
Vetri Sudar Jayaprakasam
VPViktoriya Paroder
Viktoriya Paroder
PGPeter Gibbs
Peter Gibbs
RBRaazi Bajwa
Raazi Bajwa
NGNatalie Gangai
Natalie Gangai
MGMarc J. Gollub
Marc J. Gollub

1 June 2018 in Radiology
Verified
Journal Article
Closed access
ESElizabeth A. Sadowski
Elizabeth A. Sadowski
VPViktoriya Paroder
Viktoriya Paroder
KPKrupa Patel-Lippmann
Krupa Patel-Lippmann
JRJessica B. Robbins
Jessica B. Robbins
LBLisa Barroilhet
Lisa Barroilhet
KMKatherine E. Maturen
Katherine E. Maturen
When evaluating sonographically indeterminate adnexal cysts, cyst features including avascular nodules were strongly predictive of malignancy. PurposeTo assess the prevalence of indeterminate adnexal cysts in women presenting to academic medical centers for pelvic ultrasonography (US), determine the incidence of malignancy, and identify cyst and patient characteristics that are predictive of malignancy.Materials and MethodsA multicenter study of US-detected adnexal cysts with appropriate follow-up (surgical pathologic examination, imaging and/or clinical examination) was conducted from January 2008 to June 2012. Indeterminate cysts were classified as category 1 (typical benign appearing cysts >5 cm) or category 2 (cysts with avascular solid components) on the basis of a combination of definitions in the existing literature. The incidence of neoplasms and malignant tumors was calculated. Patient and cyst characteristics associated with neoplasm and malignant tumors were evaluated with the χ2 test or Fisher exact test for categorical variables and the t test for continuous variables. A backward stepwise logistic regression model was performed for ...